AZN Astrazeneca PLC

41.4
-0.09  -0%
Previous Close 41.49
Open 41.63
Price To Book 10.35
Market Cap 108,615,127,154
Shares 2,623,553,796
Volume 1,382,075
Short Ratio 2.8
Av. Daily Volume 3,830,926

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 preliminary data due 3Q 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
Phase 3 MACE safety data released May 9, 2019. Non-inferior in non-dialysis, no worse risk than placebo. NDA filing due September/October 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020+.
Farxiga (Dapa-CKD)
Chronic Kidney Disease
Phase 3 data presented 18 March, 2019 noted 18% decrease in MACE events vs placebo.
Farxiga - DECLARE
Type-2 diabetes
Phase 1 trial - two patients have recorded complete responses.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data released November 1, 2017 - primary endpoint not met.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 data due 2020.
Farxiga (Dapa-HF)
Heart failure
Phase 3 data released May 30, 2018. Primary endpoint not met.
Benralizumab - TERRANOVA
COPD
Phase 3 data due 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020 or later.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data due 2H 2019.
PT010
Chronic obstructive pulmonary disease (COPD)
FDA approval announced September 13, 2018.
Moxetumomab
Cancer - leukaemia
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data 2H 2019.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data released December 7, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data released April 24, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (ARCTIC)
Non-small cell lung cancer (NSCLC)
Approval announced February 19, 2018.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data released February 25, 2019 met primary endpoint.
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data are due estimate 2H 2019.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Approval announced October 31, 2017.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017. Approval announced May 18, 2018.
Lokelma (ZS-9)
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Approval announced November 14, 2017.
Benralizumab
Severe, uncontrolled asthma
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data met primary and secondary endpoints. ORR; 72.2% vs 51.4% for chemotherapy. PFS 13.4 months vs 9.2 months for chemo arm (HR 0.62).
Lynparza - SOLO 3
Third-line ovarian cancer
Phase 3 data at ASCO noted median PFS 7.4 months vs 3.8 months for placebo. HR 0.53.
Lynparza (POLO)
Pancreatic cancer
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (POSEIDON)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (CASPIAN)
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
Phase 3 trial did not meet primary endpoint - noted May 11, 2018.
Fasenra (benralizumab) - GALATHEA
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2019.
Lynparza
Castration-Resistant Prostate Cancer
Phase 3 data June 6, 2019 met primary endpoint.
Calquence
1st line - Chronic lymphocytic leukaemia
Phase 3 data due 2H 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 1b/2 data likely due 2019.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 final OS data due 2H 2019.
Tagrisso - FLAURA
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Brilinta (THALES)
Acute ischaemic stroke
Phase 3 data due 2020.
Epanova
Hypertriglyceridaemia CVOT
Phase 3 data due 2020.
Fasenra
Nasal polyps
Phase 3 data due 2020.
Imfinzi
Neoadjuvant NSCLC
Phase 2 trial met primary endpoint - noted April 4, 2019.
Fasenra
Hypereosinophilic Syndrome
Phase 3 data due 2020+.
Trastuzumab deruxtecan - DESTINY-Breast04
HER low breast cancer
Phase 3 data due 2020+.
Trastuzumab deruxtecan - DESTINY-Breast03
Second line HER2+ breast cancer
Phase 3 data due 2020+.
Trastuzumab deruxtecan DESTINY-Breast02
Third line HER2+ breast cancer
Phase 2 data met primary endpoint - May 8, 2019. BLA filing due 2H 2019.
Trastuzumab deruxtecan - - DESTINY-Breast01
Third line HER2+ breast cancer
Phase 3 data due 2020+.
Fasenra
Asthma
Phase 3 data due 2020+.
Farxiga (Deliver)
Chronic Heart Failure (CHF), preserved ejection fraction (HFpEF)
Phase 3 positive interim data released May 7, 2019. Trial to be stopped early.
Calquence
Relapsed/refractory chronic lymphocytic leukaemia
FDA approval announced May 3, 2019.
Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)
Type 2 diabetes

Latest News

  1. Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
  2. Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
  3. Investors Chronicle: Telecom Plus, International Consolidated Airlines, AstraZeneca
  4. AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
  5. Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients
  6. How AstraZeneca Is Advancing Its Oncology Portfolio in 2019
  7. AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
  8. AstraZeneca’s Lynparza Continues to Dominate
  9. AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
  10. UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
  11. Tagrisso: AstraZeneca’s Top-Selling Drug in Q1
  12. How Are AstraZeneca’s Revenues Trending in 2019?
  13. What Analysts Recommend for Merck and AstraZeneca in June
  14. AstraZeneca Gives Detailed Data From Calquence Leukemia Study
  15. CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
  16. Is AstraZeneca plc (AZN) A Good Stock To Buy?
  17. Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
  18. LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis
  19. Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
  20. The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca